Axcella Health (NASDAQ:AXLA – Get Rating) and Amgen (NASDAQ:AMGN – Get Rating) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, earnings and profitability.
Valuation & Earnings
This table compares Axcella Health and Amgen's gross revenue, earnings per share (EPS) and valuation.
Get Axcella Health alerts:| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Axcella Health | N/A | N/A | -$64.63 million | ($1.66) | -0.38 |
| Amgen | $25.98 billion | 5.27 | $5.89 billion | $12.47 | 20.57 |
Amgen has higher revenue and earnings than Axcella Health. Axcella Health is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Axcella Health and Amgen, as reported by MarketBeat.com.| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Axcella Health | 0 | 2 | 2 | 0 | 2.50 |
| Amgen | 4 | 4 | 4 | 0 | 2.00 |
Axcella Health presently has a consensus price target of $5.25, suggesting a potential upside of 733.33%. Amgen has a consensus price target of $253.57, suggesting a potential downside of 1.16%. Given Axcella Health's stronger consensus rating and higher probable upside, equities research analysts clearly believe Axcella Health is more favorable than Amgen.
Volatility and Risk
Axcella Health has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500.
Profitability
This table compares Axcella Health and Amgen's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Axcella Health | N/A | -567.25% | -147.10% |
| Amgen | 25.96% | 287.23% | 16.16% |
Insider and Institutional Ownership
71.1% of Axcella Health shares are owned by institutional investors. Comparatively, 75.5% of Amgen shares are owned by institutional investors. 6.5% of Axcella Health shares are owned by company insiders. Comparatively, 0.5% of Amgen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Amgen beats Axcella Health on 9 of the 13 factors compared between the two stocks.
About Axcella Health
(Get Rating)
Axcella Health, Inc. is a biotechnology company. It engages in the research and development of treatment for diseases and improves health using endogenous metabolic modulator, or EMM, and compositions. Its product pipeline includes AXA1665, for the reduction in risk of recurrent overt hepatic encephalopathy, and AXA1125, for non-alcoholic steatohepatitis. The company was founded by Noubar B. Afeyan, Geoffrey von Maltzahn, and David A. Berry on August 27, 2008 and is headquartered in Cambridge, MA.
About Amgen
(Get Rating)
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
Receive News & Ratings for Axcella Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axcella Health and related companies with MarketBeat.com's FREE daily email newsletter.